On Jul. 30, 2020, Johnson & Johnson announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, showed the Companyﾒs investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by ﾓneutralizing antibodies,ﾔ successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study.